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OBJECTIVE—Insulin released by the -cell is thought to act
locally to regulate glucagon secretion. The possibility that insulin
might also act centrally to modulate islet glucagon secretion has
received little attention.
RESEARCH DESIGN AND METHODS—Initially the counter-
regulatory response to identical hypoglycemia was compared
during intravenous insulin and phloridzin infusion in awake
chronically catheterized nondiabetic rats. To explore whether
the disparate glucagon responses seen were in part due to
changes in ventromedial hypothalamus (VMH) exposure to insu-
lin, bilateral guide cannulas were inserted to the level of the VMH
and 8 days later rats received a VMH microinjection of either 1)
anti-insulin afﬁbody, 2) control afﬁbody, 3) artiﬁcial extracellular
ﬂuid, 4) insulin (50 U), 5) insulin receptor antagonist (S961), or
6) anti-insulin afﬁbody plus a -aminobutyric acid A (GABAA)
receptor agonist muscimol, prior to a hypoglycemic clamp or
under baseline conditions.
RESULTS—As expected, insulin-induced hypoglycemia pro-
duced a threefold increase in plasma glucagon. However, the
glucagon response was fourfold to ﬁvefold greater when circu-
lating insulin did not increase, despite equivalent hypoglycemia
and C-peptide suppression. In contrast, epinephrine responses
were not altered. The phloridzin-hypoglycemia induced glucagon
increase was attenuated (40%) by VMH insulin microinjection.
Conversely, local VMH blockade of insulin ampliﬁed glucagon
twofold to threefold during insulin-induced hypoglycemia. Fur-
thermore, local blockade of basal insulin levels or insulin recep-
tors within the VMH caused an immediate twofold increase in
fasting glucagon levels that was prevented by coinjection to the
VMH of a GABAA receptor agonist.
CONCLUSIONS—Together, these data suggest that insulin’s
inhibitory effect on -cell glucagon release is in part mediated at
the level of the VMH under both normoglycemic and hypoglyce-
mic conditions. Diabetes 59:1521–1527, 2010
T
he pancreatic -cell is the primary regulator of
glucose homeostasis and glucagon secretion
(1,2). In the presence of changes in blood glu-
cose concentration, local changes in insulin to-
gether with zinc and/or -aminobutyric acid (GABA)
release from the -cell are thought to act in concert to
regulate -cell glucagon secretion (3,4). However, during
hypoglycemia the central nervous system (5,6), and the
VMH in particular, also plays a critical role in stimulating
the release of glucagon and other counterregulatory hor-
mones, via changes in the activity of specialized glucose-
sensing neurons (7–10). Moreover, mice with selective loss
of glutamate release in steroidogenic factor 1 neurons,
which are expressed exclusively in the VMH, show a
markedly impaired glucagon secretory response to acute
hypoglycemia (11). These and other studies suggest that
central regulation of pancreatic -cell glucagon secretion
may play a greater role than previously anticipated, at
least during insulin-induced hypoglycemia (2,6–8).
The fact that the VMH may directly inﬂuence -cell
glucagon release, and that glucose-sensing neurons in the
VMH appear to use similar mechanisms for detecting
ﬂuctuations in glucose to the pancreatic - and -cells
(7,8), suggested that insulin might play a similar regulatory
role through a central mechanism. The possibility that
insulin might exert a central effect is consistent with
evidence that brain insulin levels mirror those in the
circulation (12), that glucose-sensing neurons express
insulin receptors, and that insulin alters the ﬁring rate of
these neurons (8,13–15). Moreover, insulin has been re-
ported to act on the hypothalamus to regulate hepatic
glucose production (16). However, studies in humans
evaluating whether the level of circulating insulin during
exogenous insulin administration inﬂuences counterregu-
latory hormone responses have yielded conﬂicting results.
It has been reported that higher levels of plasma insulin
may amplify (17,18) or inhibit (19–21) epinephrine re-
sponses during hypoglycemia. One study noted a signiﬁ-
cant effect of circulating insulin on accompanying
glucagon responses, speciﬁcally an inhibitory action (20).
Whether insulin acts centrally to inﬂuence glucose coun-
terregulation is also uncertain. In animal studies, insulin
delivered directly into the brain in very large doses has
been reported to amplify counterregulatory hormone se-
cretion (22–24) or to have no direct effect (25).
This study was undertaken to determine whether insulin
acts within the ventromedial hypothalamus (VMH) to
modulate the secretion of glucoregulatory hormones. For
this purpose, we either blocked insulin action or adminis-
tered insulin to the VMH, during hypoglycemia produced
in the presence or absence of elevated circulating insulin
levels, respectively. In addition, we examined whether
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regulate glucoregulatory hormone secretion in the ab-
sence of elevated levels of insulin. Our ﬁndings provide in
vivo evidence for the ﬁrst time that insulin acts within the
VMH to inﬂuence the release of glucagon from -cells both
during hypoglycemia and under basal conditions.
RESEARCH DESIGN AND METHODS
Animal preparation for in vivo experiments. Adult male Sprague Dawley
rats (Charles River Laboratories, Wilmington, MA) were studied. Animals
were housed in individual cages in the Yale Animal Resource Center, fed a
standard pellet diet (Agway Prolab 3000, Syracuse, NY), and maintained on a
12-h day/night cycle. At 7–10 days before each study, rats were anesthetized
with an intraperitoneal injection (1 ml/kg) of a mixture of xylazine (AnaSed 20
mg/ml; Lloyd Laboratories, Shenandoah, IA) and ketamine (Ketaset 100
mg/ml; Aveco Co., Fort Dodge, IA) in a ratio of 1:2 (vol:vol). The rats initially
underwent vascular surgery for the implantation of chronic vascular cathe-
ters, in the right internal jugular vein and the left carotid artery as described.
The catheters (PE50 tubing with a tip made from silastic laboratory tubing
[0.51 mm intradermally]) are inserted via a neck incision into the internal
jugular vein and carotid artery and extended to the level of the right atrium
and aortic arch, respectively. They are then tunneled subcutaneously and
externalized at the nape of the neck where the catheter ends are left free. The
patency of catheters is maintained by ﬁlling them with a heparin/polyvinylpyr-
rolidone solution; the venous catheter was used for infusions and the artery,
for blood sampling. In addition, bilateral microinjection guide cannulas were
stereotaxically inserted 1 mm above the VMH for delivery of test substances
as described previously (26). Experimental protocols are in accordance with
laboratory animal care guidelines and were approved by the Yale Animal Care
and Use Committee.
In vivo experiments. Metabolic experiments were conducted 8 days after
complete recovery from surgery. Insulin was diluted and phloridzin dissolved
in saline. All microinjected solutions were diluted in artiﬁcial extracellular
ﬂuid (aECF). Prior to the start of experiments, animals were fasted overnight
and in the morning they were studied while awake and able to move about
their cages. Initially, blood was withdrawn to assess baseline hormone levels.
Thereafter, animals received bilateral microinjections via the guide cannulas
of either aECF (n  6), insulin (50 U) (n  8), control afﬁbody (1 g) (n 
8), anti-insulin afﬁbody (AB31906, 1 g; Abcam, Cambridge MA) (n  8),
anti-insulin afﬁbody  muscimol (1 nmol/l) (n  6), or high-afﬁnity insulin
receptor antagonist S961 (1 g) (Novo Nordisk, Bagsvaerd, Denmark) (n  6).
Afﬁbody molecules mimic antibodies in function but have advantages of a
smaller size (6 kDa) and stability. After microinjection, hypoglycemic
clamps were performed for 90 min using either an insulin (6 mU/kg/min) or
phloridzin (100 g/kg/min) infusion and ﬁxing blood glucose at 70 mg/dl
using a variable rate glucose infusion. Blood samples were collected at 0, 30,
60, and 90 min for measurement of plasma glucagon, C-peptide, and insulin by
radioimmunoassay (Linco Research) and catecholamines using high-perfor-
mance liquid chromatography. Peak glucagon responses occurred at 60 min.
After each sample collection, the erythrocytes were resuspended in an
equivalent volume of artiﬁcial plasma and reinfused back into the animal to
prevent volume depletion and anemia. Animals were killed using sodium
pentobarbital and the brains removed and frozen in dry ice. Subsequently, the
accuracy of probe placements was determined by histological inspection of
coronal brain sections. Only data obtained from animals in which the probes
were positioned beside the VMH were used (15% of the animals were
excluded).
In vitro and in vivo validation of the anti-insulin afﬁbody. 3T3L1 cells
were cultured to conﬂuence in high-glucose Dulbecco’s modiﬁed Eagle’s
medium containing 10% bovine growth serum (Hyclone) and 1% penicillin-
streptomycin. Conﬂuent cells were then differentiated using high-glucose
Dulbecco’s modiﬁed Eagle’s medium containing 10% FBS, isobutylmethylxan-
thine, insulin, and dexamethasone, as described (27). Cells were considered
fully mature 8 days after the induction of differentiation. After complete
differentiation, cells were serum starved overnight and treated with either
PBS, 3 nmol/l insulin alone, or 3 nmol/l insulin preincubated with 10 g
anti-insulin afﬁbody. After stimulation, cells were washed with ice-cold PBS
and total protein was isolated. Total cell lysate (15 g) was subjected to
Western blotting and membranes were probed using antibodies against p-Akt
(no. 9271; Cell Signaling) or glyceraldehyde-3-phosphate dehydrogenase
(Sigma). For in vivo validation studies, hypoglycemic clamps were conducted
with VMH anti-insulin or control afﬁbody microinjection, as described above,
and brains from animals were collected at 30 min. The brains were sectioned
and total protein from VMH micropunches was obtained. Akt phosphorylation
in the VMH in response to insulin treatment was analyzed using Western
blotting using antibodies against p-Akt and normalized against -actin as a
loading control. These studies conﬁrmed the insulin-blocking action of the
afﬁbody in vitro and in vivo. Addition of the anti-insulin afﬁbody in vitro
prevented the phosphorylation of Akt in 3T3L1 cells (Fig. 1A), and VMH
microinjection of anti-insulin afﬁbodies suppressed the 2.5-fold local increase
in Akt phosphorylation produced during insulin-induced hypoglycemia (Fig.
1B).
Additional methods. All values are mean  SEM. Treatment effects were
analyzed using repeated-measures two-way ANOVA followed by post hoc
analysis to localize effects or two-tailed Student t tests as appropriate using
the Prism analytical software. P 	 0.05 was set as the criterion for statistical
signiﬁcance.
RESULTS
Glucagon responses to insulin- versus phloridzin-
induced hypoglycemia. To test the effects of circulating
insulin on glucagon responses to hypoglycemia, we intra-
venously infused rats with either insulin or phloridzin and
allowed plasma glucose to fall to 70 mg/dl using the
glucose clamp technique. Plasma insulin declined with
phloridzin (7  1t o4 1 U/ml) and rose with insulin
(8  1t o1 5 1 21 U/ml) infusion, but plasma glucose
was identically reduced in both groups (Fig. 1). The
exogenous glucose infusion rate (GIR) to maintain identi-
cal hypoglycemia was, however, markedly higher with
insulin hypoglycemia compared with phloridzin (8.7  0.3
vs. 0.5  0.1 mg/kg/min; insulin vs. phloridzin P 	 0.01).
Glucagon levels increased during both phloridzin-induced
(33  12 baseline to 777  122 ng/l) and insulin-induced
(55  10 to 178  45 ng/l) hypoglycemia (P 	 0.01),
however, the magnitude of the rise was fourfold to ﬁvefold
greater in the absence of systemic hyperinsulinemia. This
difference occurred despite identical 70–90% decreases in
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FIG. 1. Insulin-induced phosphorylation of Akt is prevented by delivery
of anti-insulin afﬁbodies to differentiated adipocytes in vitro (A) and
into the ventromedial hypothalamus in vivo during systemic insulin
infusion. Relative change in Akt phosphorylation was normalized to
-actin (B). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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catecholamines (Fig. 2). To evaluate whether the phlorid-
zin infusion might act directly to stimulate glucagon secre-
tion, we administered phloridzin while maintaining
euglycemia using a variable glucose infusion. Under these
conditions, plasma glucagon remained unchanged (38 
12 baseline vs. peak levels of 55  11 ng/l during clamp,
n  6; P  not signiﬁcant [NS]), suggesting the lack of a
direct effect on -cell secretion. Because these studies do
not distinguish between the relative contribution of in-
traislet and hypothalamic insulin to the disparate glucagon
response, additional studies were conducted to manipu-
late VMH insulin action under hyperinsulinemic and hypo-
insulinemic hypoglycemia.
VMH insulin action suppresses glucagon response to
insulin-induced hypoglycemia. To investigate whether
the observed disparate glucagon responses to hypoglyce-
mic stimuli could at least in part be attributed to differ-
ences in the exposure of the VMH to insulin, we
microinjected speciﬁc anti-insulin or control (noninsulin
binding) afﬁbodies bilaterally into the VMH to locally bind
and reduce local insulin levels during a 6 mU/kg/min
hyperinsulinemic hypoglycemic clamp. Blockade of insu-
lin action within the VMH reduced by 50% the GIR required
to maintain the same hypoglycemic plateau compared
with microinjection of a control afﬁbody (4.4  0.4 anti-
insulin afﬁbody vs. 8.7  0.3 mg/kg/min control, P 	 0.05).
This effect was associated with a 2.5-fold greater glucagon
increase in rats that received the VMH anti-insulin afﬁbody
(430  95 anti-insulin afﬁbody vs. 178  45 ng/l control
afﬁbody; P 	 0.05). In contrast, blockade of insulin within
the VMH had no effect on the suppression of either
C-peptide or catecholamine levels during hypoglycemia,
suggesting that insulin acts directly on the VMH to
selectively suppress glucagon secretion independent of
intraislet insulin or input from circulating cat-
echolamines (Fig. 3).
VMH insulin microinjection suppresses glucagon re-
sponse to phloridzin hypoglycemia. Conversely, when
insulin (50 U) or aECF (control) was microinjected
bilaterally into the VMH during a phloridzin hypoglycemic
clamp study, local insulin delivery reduced glucagon-
mediated counterregulation. Local VMH insulin delivery
caused an increase in the glucose infusion rate required to
maintain the same hypoglycemic plateau (1.7  0.2 VMH
insulin vs. 0.4  0.1 mg/kg/min control, P 	 0.05) and
suppressed glucagon levels by 40% (777  122 control vs.
498  60 ng/l insulin, P 	 0.05; Fig. 3). No signiﬁcant
changes were observed in plasma insulin, C-peptide, or
catecholamines levels. The inability of VMH insulin deliv-
ery to completely suppress the glucagon response to
phloridzin hypoglycemia to levels seen with insulin-in-
duced hypoglycemia may be due to insulin actions within
other target areas, such as the islet.
Local blockade of VMH insulin increases basal gluca-
gon levels. To examine whether the -cell might regulate
basal -cell glucagon secretion via insulin delivery to the
VMH in the absence of exogenous insulin, we microin-
jected either 1) an anti-insulin afﬁbody (or a control
afﬁbody), 2) a potent insulin receptor antagonist (28)
(S961; Novo Nordisk), or 3) aECF bilaterally into the VMH
of awake overnight-fasted rats. As shown in Fig. 4, block-
ade of endogenous VMH insulin action (anti-insulin afﬁ-
body) caused an immediate twofold increase in plasma
glucagon within 5 min. This resulted in a rise in plasma
glucose (15  5 mg/dl), limited by a small but insigniﬁcant
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FIG. 2. Effect of circulating insulin on plasma glucagon, epinephrine, and C-peptide responses to an equivalent fall in plasma glucose produced
by infusion of insulin or phloridzin. The absence of an elevation in circulating insulin magniﬁed the glucagon response, despite identical
suppression of C-peptide increments of epinephrine. *P < 0.05.
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Similarly, VMH delivery of the speciﬁc insulin receptor
antagonist increased plasma glucagon twofold. Plasma
glucose levels rose by 10–15 mg/dl, and this was also
followed by a small, but nonsigniﬁcant rise in circulating
insulin. Thus, regardless of the method used to reduce
insulin action within the VMH, fasting glucose levels rose
because of rapid disinhibition of glucagon secretion. No
such changes in either study were observed in control
animals (Fig. 4). The rapid increase in glucagon release
caused by local blockade of VMH insulin was completely
abolished by the simultaneous injection of muscimol (Fig.
4). In contrast, we have previously shown that in over-
night-fasted rats VMH microinjection of muscimol alone
has no effect on either glucagon or glucose levels (29).
Thus, insulin’s effect on the VMH may be mediated, at least
in part, by an enhancement of local GABA tone.
DISCUSSION
Insulin regulates glucose homeostasis through its actions
on multiple sites, including the liver, muscle, and adipose
tissue (30). Insulin also exerts important effects on the
central nervous system, including neural development,
satiety/feeding, cognitive function, and aging (31,32). Glu-
cagon release from the neighboring -cell, a major deter-
minant of hepatic glucose production, has also been
shown to be under the control of insulin levels within the
islet (2,33). The current study extends these observations
by providing evidence that in addition to its local paracrine
action, insulin acts in the VMH to inﬂuence and possibly
ﬁne-tune the release of pancreatic glucagon under both
hypoglycemic and fasting conditions. Previous studies
from our laboratory have demonstrated that a variety of
factors involved in glucose sensing by VMH neurons and
the neurotransmitter input to these neurons, such as
GABA, generally alter both glucagon and sympathoadrenal
counterregulatory responses (26). Thus, the failure of
VMH insulin delivery to act similarly and simultaneously
alter the sympathoadrenal response to hypoglycemia im-
plies that separate neural pathways might activate gluca-
gon and sympathoadrenal responses to glucose
deprivation, or that those other systems contribute to a
ﬁnal common pathway, thereby altering both responses. It
is noteworthy in this regard that mice lacking VGLUT2
speciﬁcally in steroidogenic factor 1 neurons (a major
subset of VMH neurons), and thus unable to release
glutamate from these neurons, show a much more pro-
found effect on glucagon than catecholamine release in
response to glucopenia (11). The possibility that the brain
and pancreas operate in concert to control glucagon
secretion is consistent with the reported similarities found
between the mechanisms used by glucose-sensing -cells
and their neuronal counterparts in the VMH (8).
In contrast to the current ﬁndings, previous studies
using neuronal insulin receptor knockout mice suggested
that brain insulin ampliﬁes catecholamine but not gluca-
gon responses to hypoglycemia (24). The differences be-
tween our ﬁndings and those studies may be explained by
developmental adaptations within the central nervous
system and/or the global neuronal insulin receptor knock-
down produced in the neuronal insulin receptor knockout
mouse. Moreover, a recent study failed to detect an effect
of brain insulin infusion on catecholamine or glucagon
responses to hypoglycemia or glucoprivation (25). How-
ever, those observations may be complicated by the very
large pharmacological doses of exogenous insulin deliv-
ered to the brain. In the current study, the role of insulin in
glucose counterregulation was assessed by two comple-
mentary approaches. Phloridzin or insulin was infused
peripherally to compare the hormone response with a
comparable fall in plasma glucose in the presence or
absence of insulin. These studies demonstrated marked
differences in glucagon secretory responses, however, the
tissues responsible for the disparate response to the two
hypoglycemias could not be established with this ap-
proach. To explore this question, we locally increased or
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sensing region, during infusion of phloridzin and insulin,
respectively. We used a mild hypoglycemic stimulus (70
mg/dl) that minimized the confounding effects on pancre-
atic glucagon secretion of simultaneous marked increases
in sympathoadrenal activity caused by more severe hypo-
glycemia. Such increases independently stimulate -cell
glucagon secretion.
It should be noted that although our microinjection
probes were directed predominately at the ventromedial
nucleus of the VMH (which includes both the ventromedial
and arcuate nucleus), very small volumes were used, and
because this approach largely restricts delivery of agents
to the VMH, it is difﬁcult to completely limit spread to
neighboring areas (34). Thus, we cannot exclude the
possibility that spillover effects to surrounding regions
might also have contributed to the observed changes in
glucagon secretion. It is noteworthy in this regard that
genetically engineered mice with predominant absence of
insulin receptors in hypothalamic neurons display hepatic
insulin resistance (30). Furthermore, conditional knock-in
of insulin receptors in Agouti related peptide (Agrp)
neurons of these mice reduced hepatic glucose production
(glucagon was not measured) (35). Whether the effects
seen during VMH microinjection in the current study
reﬂect spread to Agrp neurons in the arcuate nucleus
remain uncertain. In addition, previous studies have dem-
onstrated that delivery of insulin into the hypothalamus
directly suppresses hepatic glucose production (16). Thus,
we cannot exclude the possibility that direct stimulation of
glucose release from the liver as well as stimulation of
glucagon secretion contributed to the lower glucose infu-
sion rates observed after blockade of VMH insulin during
the clamp study. Finally, our observation that systemic
insulin delivery increases Akt phosphorylation within the
VMH is consistent with previous studies showing that
insulin exerts its effects on the hypothalamus via activa-
tion of the phosphatidylinositol 3 kinase signaling pathway
(36).
Of particular interest, insulin within the VMH also
appears to regulate glucagon secretion under basal condi-
tions, lending even greater signiﬁcance to the role of
hypothalamic insulin action in glycemic regulation. Block-
ade of insulin action in the VMH by two separate mecha-
nisms caused an immediate increase in plasma glucagon in
the absence of a decline in insulin secretion. These ﬁnd-
ings support the view that the hyperglucagonemia was
induced at the level of the VMH rather than the islet and
raise the possibility that impaired VMH insulin action may
also contribute to disordered systemic glucose regulation.
This view is consistent with reports of the development of
a diabetes phenotype in Drosophila after ablation of brain
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knockdown of brain insulin receptors (38).
With respect to the possible mechanism for insulin’s
effect within the VMH, studies conducted in islets have
shown that GABA is released from the -cells together
with insulin and that insulin acts on the -cell to increase
GABAA receptor trafﬁcking to the cell surface, thereby
enhancing GABA’s inhibitory effect on glucagon secretion
(39,40). Moreover, we have reported that VMH GABAergic
tone exerts a powerful effect on the counterregulatory
response to hypoglycemia (26,29). GABA levels in VMH
interstitial ﬂuid decrease in response to hypoglycemia,
promoting hormone release (26), whereas inappropriately
elevated GABA levels in the VMH appear to contribute to
the absent glucagon response to insulin-induced hypogly-
cemia observed in rodent models of type 1 diabetes (O.C.,
unpublished observations). It has also been reported that
insulin exerts direct electrophysiological effects on neu-
rons in vivo, which may be inﬂuenced by GABAergic
inputs (14). The observation that GABAA receptor antag-
onist reverses insulin’s effect on the VMH implies that
insulin may act by enhancing GABAergic tone in the VMH,
as is seen in the islet (38,39). In addition to potential
effects of insulin on GABAergic tone within the VMH,
studies have demonstrated that VMH ATP-sensitive K

channel activity inﬂuences both glucose counterregulation
and hepatic gluconeogenesis (41). These studies coupled
with data showing insulin’s effects on the opening of
ATP-sensitive K
 channels (41,42) make this a plausible
downstream mechanism, which might explain the effects
observed here. The striking similarities between the func-
tioning of the pancreatic -cells and glucose-sensing neu-
rons, as well as evidence that insulin functions as a
neuronal peptide in more primitive organisms, are in
keeping with the emerging view that the brain and the
pancreatic islet share common evolutionarily conserved
mechanisms (7,43,44).
The current study does not, however, suggest that
insulin within the VMH has the primary role in regulation
of glucagon secretion. Intraislet insulin undoubtedly plays
a critical role in glucagon secretion. This view is supported
by our failure to see complete suppression of the glucagon
response during local VMH insulin delivery during phlo-
ridzin-induced hypoglycemia. The suppressive effect of
local insulin was less than 50%. Moreover, a recent study
reported a very similar effect of insulin signaling in the
islet to regulate glucagon release (33). On the other hand,
given that the rise in basal glucagon levels observed after
VMH insulin blockade was not accompanied by a fall in
endogenous insulin secretion and that C-peptide was
suppressed to the same extent irrespective of our treat-
ment manipulations, it is unlikely that the marked differ-
ences in glucagon responses can be attributed solely to
differences in intraislet insulin levels.
The primary metabolic evolutionary challenge faced by
humans has been starvation, during which insulin and
glucose levels decrease in unison, thereby releasing the
restraining effect of insulin on the -cell at the level of both
the islet (45,46), and the VMH. This results in an appropri-
ate disinhibition of glucagon secretion, allowing the re-
lease of stored glucose from the liver. The current data
suggest that the decrease in glucose provoked by systemic
insulin administration may be not only perceived as a
signal of metabolic deprivation but also seen as a signal of
concomitant food availability, thereby resulting in a muted
or maladaptive glucagon response. It is noteworthy that a
similar enhancement of glucagon secretion has been re-
ported with drug-induced insulin-independent decrements
in blood glucose in the dog, which was attributed to
suppression of intraislet insulin, but that is equally consis-
tent with the loss of the central inhibitory actions of
insulin (47). One might speculate that the loss of glucagon
response to hypoglycemia in type 1 diabetic patients
lacking endogenous insulin might result in part from the
simultaneous increase in insulin levels both in the VMH
and locally in the islet caused by exogenous insulin
administration. This possibility is consistent with our
previous report showing marked stimulation of glucagon
and epinephrine release in diabetic BB rats when hypogly-
cemia was produced by systemic infusion of 5
-aminoimi-
dazole-4-carboxymide-1--D-ribofuranoside (a chemical
activator of AMP-kinase) and phloridizin rather than insu-
lin (48).
We conclude that -cell insulin secretion acts to inhibit
-cell glucagon secretion both at the level of the islet and
the VMH. Insulin’s central effect appears to occur under
hypoglycemia as well as basal conditions and thus might
contribute to disorders of glucose homeostasis.
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